{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:29:02Z","timestamp":1783625342352,"version":"3.55.0"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,1,5]]},"DOI":"10.18632\/oncotarget.6353","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T11:55:29Z","timestamp":1448020529000},"page":"255-265","source":"Crossref","is-referenced-by-count":42,"title":["Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition"],"prefix":"10.18632","volume":"7","author":[{"given":"Martina","family":"Di Modica","sequence":"first","affiliation":[{"name":"Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sfondrini","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche per la Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Regondi","sequence":"additional","affiliation":[{"name":"Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Varchetta","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Oliviero","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Mariani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Valeria","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[{"name":"Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Balsari","sequence":"additional","affiliation":[{"name":"Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Dipartimento di Scienze Biomediche per la Salute, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Triulzi","sequence":"additional","affiliation":[{"name":"Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Tagliabue","sequence":"additional","affiliation":[{"name":"Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,11,21]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ctrv.2008.03.013","article-title":"Adjuvant\/neoadjuvant trastuzumab therapy in women with HER-2\/neu-overexpressing breast cancer: a systematic review","volume":"34","author":"Messersmith","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2007-0204","article-title":"Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer","volume":"13","author":"Blackwell","year":"2008","journal-title":"Oncologist"},{"key":"3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","article-title":"Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen","volume":"13","author":"Hortobagyi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","article-title":"Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer","volume":"29","author":"Jenkins","year":"2011","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ctrv.2011.06.002","article-title":"Activity and resistance mechanisms of trastuzumab in different clinical settings","volume":"38","author":"Balsari","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"6","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Blackwell","year":"2009","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1158\/1078-0432.CCR-03-0549","article-title":"A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies","volume":"10","author":"Vitetta","year":"2004","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Coudert","year":"2006","journal-title":"Br J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Costa","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2","volume":"67","author":"Fagnoni","year":"2007","journal-title":"Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Levy","year":"2012","journal-title":"J Clin Invest"},{"key":"12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Raulet","year":"2005","journal-title":"Nature"},{"key":"13","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1158\/0008-5472.CAN-11-0792","article-title":"Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition","volume":"71","author":"Olive","year":"2011","journal-title":"Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-05-2520","article-title":"Proteolytic release of soluble UL16-binding protein 2 from tumor cells","volume":"66","author":"Steinle","year":"2006","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"Carson","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"16","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/bjc.2014.196","article-title":"Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy","volume":"110","author":"Generali","year":"2014","journal-title":"Br J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Cerwenka","year":"2008","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.4049\/jimmunol.1202065","article-title":"Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions","volume":"189","author":"Bousso","year":"2012","journal-title":"J Immunol"},{"key":"19","doi-asserted-by":"crossref","first-page":"10121","DOI":"10.1158\/0008-5472.CAN-10-1047","article-title":"Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response","volume":"70","author":"Shin","year":"2010","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bjc.6603840","article-title":"NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy","volume":"97","author":"Mellstedt","year":"2007","journal-title":"Br J Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1084\/jem.20122220","article-title":"Diverse novel functions of neutrophils in immunity, inflammation, and beyond","volume":"210","author":"Mocsai","year":"2013","journal-title":"J Exp Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","article-title":"Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes","volume":"87","author":"Boulamatsis","year":"2002","journal-title":"Br J Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Lundqvist","year":"2014","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1158\/1078-0432.CCR-13-0866","article-title":"Molecular pathways: myeloid complicity in cancer","volume":"20","author":"Hingorani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2008-03-143776","article-title":"Mononuclear myeloid-derived \u201csuppressor\u201d cells express RAE-1 and activate natural killer cells","volume":"112","author":"Cerwenka","year":"2008","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Slamon","year":"2004","journal-title":"J Natl Cancer I"},{"key":"28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CAD.0b013e32834120aa","article-title":"Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials","volume":"22","author":"Barni","year":"2011","journal-title":"Anticancer Drugs"},{"key":"29","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Hortobagyi","year":"2005","journal-title":"J Clin Oncol"},{"key":"30","first-page":"13","article-title":"Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro","volume":"56","author":"Kudo","year":"2002","journal-title":"Acta Med Okayama"},{"key":"31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.exphem.2006.02.015","article-title":"The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells","volume":"34","author":"Uharek","year":"2006","journal-title":"Exp Hematol"},{"key":"32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Ugolini","year":"2011","journal-title":"Science"},{"key":"33","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Fu","year":"2010","journal-title":"Cancer Cell"},{"key":"35","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Smyth","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"36","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Sotiriou","year":"2014","journal-title":"Ann Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2014.57.6298","article-title":"Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial","volume":"33","author":"Reinholz","year":"2015","journal-title":"J Clin Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Djeu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jcp.22257","article-title":"Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility","volume":"225","author":"Pupa","year":"2010","journal-title":"J Cell Physiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T16:41:55Z","timestamp":1589215315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,5]]}},"alternative-id":["6353","26595802"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6353","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,21]]}}}